Markets:

Overview

News

Currencies

International

Treasuries

CymaBay Therapeutics Inc. - Common Stock (NQ:CBAY)

N/A UNCHANGED

Last Price Updated: 4:00 PM EDT, Mar 21, 2024 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about CymaBay Therapeutics Inc. - Common Stock

< Previous 1 2 3 4 Next >

Analyst Expectations for CymaBay Therapeutics's Future ↗

August 31, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For August 14, 2023 ↗

August 14, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For August 11, 2023 ↗

August 11, 2023

Via Benzinga

Earnings Preview For CymaBay Therapeutics ↗

August 09, 2023

Via Benzinga

7 Analysts Have This to Say About CymaBay Therapeutics ↗

July 31, 2023

Via Benzinga

Intercept Pharma Gets Double Upgrade: Analyst Says OCA Combo Therapy Can Extend PBC Business ↗

July 13, 2023

HC Wainwright has upgraded Intercept Pharmaceuticals Inc (NASDAQ: ICPT) to Buy from Sell, with a price target of

Via Benzinga

Genfit's Miss Is CymaBay Therapeutics' Gain: Analyst Says Rival Data Leaves Room for Seladelpar To Emerge As Best-In-Class ↗

June 30, 2023

Friday, CymaBay Therapeutics Inc's (NASDAQ: CBAY) competitors Genfit SA (NASDAQ: GNFT) and Ipsen SA (OTC:

Via Benzinga

12 Health Care Stocks Moving In Friday's Intraday Session ↗

June 30, 2023

Via Benzinga

Why Cineverse Shares Are Trading Lower By 18%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗

June 30, 2023

Gainers Addentax Group Corp. (NASDAQ: ATXG) shares jumped 47.3% to $9.68. Addentax Group is launching automation of artificial intelligence internet operational tools project with top...

Via Benzinga

Why Shares of CymaBay Therapeutics Are Soaring Friday ↗

June 30, 2023

A competitor's drug had a so-so phase 3 trial, lifting the possibilities for CymaBay's lead therapy.

Via The Motley Fool

Analyst Expectations for CymaBay Therapeutics's Future ↗

June 26, 2023

Via Benzinga

Carnival, SMART Global, Friedman Industries And Other Big Stocks Moving Higher On Friday ↗

June 30, 2023

U.S. stocks traded higher, with the Dow Jones gaining more than 200 points on Friday. Here are some big stocks recording gains in today’s session.

Via Benzinga

Dow Surges 200 Points; Constellation Brands Posts Upbeat Results ↗

June 30, 2023

U.S. stocks traded higher this morning, with the Dow Jones gaining more than 200 points on Friday. Following the market opening Friday, the Dow traded up 0.63% to 34,338.23 while the NASDAQ rose 1.05%...

Via Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

June 30, 2023

Via Benzinga

Former Wall Street Darling Intercept Restructures After FDA Rejects Its Liver Drug ↗

June 23, 2023

Following the FDA rejection, Intercept will restructure to focus on rare liver diseases.

Via Investor's Business Daily

Expert Ratings for CymaBay Therapeutics ↗

May 16, 2023

Via Benzinga

CymaBay Therapeutics: Q1 Earnings Insights ↗

May 15, 2023

Via Benzinga

CymaBay Therapeutics's Earnings Outlook ↗

May 12, 2023

Via Benzinga

The Latest Analyst Ratings for CymaBay Therapeutics ↗

April 24, 2023

Via Benzinga

What Now After FDA AdComm Rebuke for Intercept Pharmaceutical? Analyst Says Approval Of Intercept's 'OCA In NASH May Never Occur ↗

May 22, 2023

On Friday, FDA's Gastrointestinal Drugs Advisory Committee voted 12 to 2—with two abstentions—that the benefits of Intercept Pharmaceutical Inc's ICPT Ocaliva 25 mg, also known as Obeticholic acid...

Via Benzinga

Why CymaBay Therapeutics Stock Nose-Dived This Week ↗

May 19, 2023

Investors did not warmly greet the latest news from the biotech.

Via The Motley Fool

Four Potential Breakout Stocks For The Rest Of The Week ↗

April 19, 2023

In trading, there will always be elegance in simplicity. If your trading operation lacks a cadre of PhDs to crunch data like Renaissance Technologies or D.E. Shaw, simplicity will always trump...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For April 5, 2023 ↗

April 05, 2023

Via Benzinga

Analyst Ratings for CymaBay Therapeutics ↗

April 05, 2023

Via Benzinga

Preview: CymaBay Therapeutics's Earnings ↗

March 15, 2023

Via Benzinga

Analyst Expectations for CymaBay Therapeutics's Future ↗

March 07, 2023

Via Benzinga

Analyst Expectations for CymaBay Therapeutics's Future ↗

February 08, 2023

Via Benzinga

Why Baudax Bio Shares Are Trading Higher By 60%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

January 24, 2023

Gainers Baudax Bio, Inc. (NASDAQ: BXRX) shares surged 59.7% to $5.03 after the company announced the outcome of its first interim analysis in a Phase II trial of BX1000 for neuromuscular blockade in...

Via Benzinga

Why CymaBay Therapeutics Shares Are Rising ↗

January 24, 2023

CymaBay Therapeutics Inc (NASDAQ: CBAY) shares are trading higher by 9.30% to $7.22 Tuesday morning. The company priced a public offering of common stock and pre-funded warrants at $7 per share and...

Via Benzinga

12 Health Care Stocks Moving In Monday's After-Market Session ↗

January 23, 2023

Via Benzinga

< Previous 1 2 3 4 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

CymaBay Therapeutics Inc. - Common Stock (NQ:CBAY)

Headline News about CymaBay Therapeutics Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today